Today, MicroVention is focused on proprietary technologies that provide therapeutic advantages for cerebral aneurysm treatment in a minimally invasive platform. The company is currently marketing two families of products: MicroPlex™ Coil System and the HydroCoil® Embolic System, its next-generation endovascular coil system. Recently launched in early 2004 were the MicroPlex XT, a unique stretch-resistant and conformal platinum coil, and the HydroCoil 10 Embolic System, a stretch-resistant and highly flexible coil for small aneurysms.

Headquartered in Aliso Viejo, California, Microvention products are sold through their direct sales force in the U.S., Canada, France, Germany and the United Kingdom and through distributors worldwide.


MicroVention's History
The Company was founded in April 1997 by Robert Rosenbluth and Brian Cox and incorporated as MicroVention, Inc. in September. MicroVention established the strategic objective of developing and marketing medical devices, which will enable or significantly improve the treatment of diseases in small vessels. Joining the team in December of 1997, Rob Greene brought key neurovascular device experience.

After development of early concepts and prototypes of devices for the treatment of acute embolic stroke and embolization of cerebral aneurysms, the company narrowed its focus to aneurysm therapy. MicroVention maintains important stroke device technology and intellectual property and continues to monitor the acute stroke therapy market as a potential future product